Press release

Press release

June 26, 2018

Major milestone – Follicum successfully develops direct-to-scalp formulation to replace intradermal injections for first-in-class peptide-based FOL-005 hair loss drug candidate

Follicum AB (“Follicum” or “Company”) today announced that the company has developed a new cosmetically appealing direct-to-scalp formulation of its leading peptide drug candidate FOL-005 for topical treatment of hair loss which will be used in future clinical trials. In Follicum’s ongoing Phase IIa study, patients with hair loss are being treated with intradermal injections […]

June 4, 2018

Follicum’s Phase IIa Hair Growth Study Fully Recruited

Follicum AB (“Follicum” or “the Company”) today announced that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany. The objective is to investigate the safety and […]

February 7, 2018

Follicum Phase IIa study of FOL-005 against hair loss approved by the German Medicines Agency

Lund, Sweden, February 7, 2018: Follicum AB (“Follicum” or “the company”) today announced it has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on patients with Alopecia (hair loss). The trial will include approximately 60 patients and […]

February 1, 2018

Lund University Bioscience AB has decided to distribute its shares in Follicum AB

Follicum AB (”Follicum”) announce that Lund University Bioscience AB (LU Bio) has had an extraordinary general meeting 31 January, 2018. It was decided that the company’s shares in Follicum, will be distributed to its LU Bio’s shareholders. The distribution is planned to occur during week 6, 2018. LU Bio has 2 320 370 shares in […]

January 29, 2018

Follicum identifies receptors in insulin-producing cells for potential new class of diabetes drugs

Lund, Sweden, January 29, 2018. Follicum AB (“Follicum”) today announced that it has successfully mapped the receptors in insulin-producing cells that bind the company’s peptides. The new knowledge represents an important milestone in the continued development of the company’s diabetes project and opens the possibility of the identified receptors becoming potential drug targets for stimulating […]

January 25, 2018

Follicum AB: Disclosure notice

As a result of the preferential rights issue in Follicum AB (“Follicum”) in October 2017, the holding of the shareholder, Lund University Bioscience AB’s has decreased to less than ten percent of votes and equity. Lund University Bioscience AB is one of the main shareholders in Follicum. As a result of the recently completed preferential […]